Syndax Pharmaceuticals Inc
(NAS:SNDX)
$
20.93
0.35 (1.7%)
Market Cap: 1.78 Bil
Enterprise Value: 1.32 Bil
PE Ratio: 0
PB Ratio: 4.10
GF Score: 42/100 - Q1 2024 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2024$22.38 (-3.45%)Earnings
- Q4 2023 Syndax Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2024$24.41 (+0.14%)Earnings
- Syndax Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 21, 2024
- Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Syndax Pharmaceuticals Inc to Host ASH Investor Event TranscriptDec 11, 2023
- Q3 2023 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2023$14.78 (+6.18%)Earnings
- Syndax Pharmaceuticals Inc to Host an Investor Call TranscriptOct 02, 2023
- Syndax Pharmaceuticals Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2023$20.35 (-0.63%)Earnings
- Syndax Pharmaceuticals Inc To Host Axatilimab AGAVE-201 Topline Data Call TranscriptJul 24, 2023
- Syndax Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Q1 2023 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2023$20.29 (+1.15%)Earnings
- Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Q4 2022 Syndax Pharmaceuticals Inc Earnings Call TranscriptFeb 28, 2023$25.35 (+3.60%)Earnings
- Syndax Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 21, 2023
- Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Syndax Pharmaceuticals Inc ASH Annual Meeting Data Update Call TranscriptDec 11, 2022
- Q3 2022 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2022$22.33 (-2.45%)Earnings
- Q2 2022 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2022$24.28 (+1.72%)Earnings
- Syndax Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Syndax Pharmaceuticals Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) TranscriptJun 02, 2022
- Syndax Pharmaceuticals Inc Targeted Oncology Panel at Citi Biopharma Co-Panel Day (Virtual) TranscriptMay 18, 2022
- Q1 2022 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2022$15.11 (-6.03%)Earnings
- Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Q4 2021 Syndax Pharmaceuticals Inc Earnings Call TranscriptMar 01, 2022$16.06 (+3.01%)Earnings
- Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Q3 2021 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 15, 2021$17.89 (-0.17%)Earnings
- Incyte Corp GVHD Update Call: Approval in cGVHD and Syndax Collaboration TranscriptSep 27, 2021
- Syndax Pharmaceuticals Inc and Incyte Corp Axatilimab Collaboration Call TranscriptSep 27, 2021
- Syndax Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2021
- Syndax Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 09, 2021$14.55 (+1.68%)Earnings
- Syndax Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Q1 2021 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 11, 2021$16.04 (+2.56%)Earnings
- Syndax Pharmaceuticals Inc - AUGMENT-101 Data Update And KOL Conference Call TranscriptApr 20, 2021
- Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 09, 2021
- Q4 2020 Syndax Pharmaceuticals Inc Earnings Call TranscriptMar 08, 2021$23.3 (-1.19%)Earnings
- Syndax Pharmaceuticals Inc ASH 2020 Axatilimab/cGVHD Conference Call TranscriptDec 06, 2020
- Syndax Pharmaceuticals Inc at Stifel Virtual Healthcare Conference TranscriptNov 18, 2020
- Q3 2020 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2020$17.09 (-1.84%)Earnings
- Syndax Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Q2 2020 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2020$15 (+0.81%)Earnings
- Syndax Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 09, 2020
- Q1 2020 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020$18.01 (-1.91%)Earnings
- Q4 2019 Syndax Pharmaceuticals Inc Earnings Call TranscriptMar 03, 2020$9.27 (-5.41%)Earnings
- Q3 2019 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2019$6.96 (-0.43%)Earnings
- Syndax Pharmaceuticals Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019$9.51 (+4.05%)Earnings
- Syndax Pharmaceuticals Inc at JMP Securities Life Science Conference TranscriptJun 20, 2019
- Syndax Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 21, 2019
- Q1 2019 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 06, 2019$7.36 (+2.79%)Earnings
- Q4 2018 Syndax Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2019$6.27 (+0.64%)Earnings
Syndax Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 08:50PM GMT
Release Date Price:
$8.82
(-0.56%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP
(technical difficulty)
.com/researchdisclosures, or at the registration desk. And I'm one of our biotechnology analysts. My name is David Lebowitz, and I'd like to welcome to the stage with me from Syndax Pharmaceuticals, CEO, Briggs Morrison. Glad to have you back again.
Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director
Good to see you, David.
David Neil Lebowitz
Morgan Stanley, Research Division - VP
Before we get started, I guess let's start with Syndax from a top level discussion. What's -- can you tell me about the company itself, where you came from and what your overall mission is.
Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director
Sure. So our overall mission is to realize a future in which people with cancer live longer and better than ever before. And our overall business strategy is to license in molecules that we think have the potential to achieve
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)